Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has earned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.7692.
Several research firms have recently issued reports on TSHA. The Goldman Sachs Group upped their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Wednesday, June 24th. Bank of America upped their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Robert W. Baird increased their price objective on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Finally, Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th.
Check Out Our Latest Research Report on TSHA
Taysha Gene Therapies Trading Down 2.7%
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts anticipate that Taysha Gene Therapies will post -0.52 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the sale, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd increased its position in shares of Taysha Gene Therapies by 143.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares during the last quarter. Guggenheim Capital LLC purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth about $61,000. R Squared Ltd bought a new position in Taysha Gene Therapies during the first quarter valued at about $50,000. Y Intercept Hong Kong Ltd bought a new position in Taysha Gene Therapies during the first quarter valued at about $51,000. Finally, Panagora Asset Management Inc. purchased a new stake in Taysha Gene Therapies during the fourth quarter worth about $64,000. Institutional investors own 77.70% of the company’s stock.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Read More
- Five stocks we like better than Taysha Gene Therapies
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
